dm+d
Unassigned
New Medicines
Renal transplant, prevention of delayed graft function in recipients of a deceased older donor kidney
Information
New molecular entity
Not Known
Quark Pharmaceuticals
Development and Regulatory status
None
Phase III Clinical Trials
Phase III Clinical Trials
Dec 21Plans for further development uncertain as PIII results not yet posted and company have no visible online presence [10].
Category
Small interfering RNA (sIRNA) that temporarily and reversibly inhibits the activity of the p53 gene.
3,250 renal transplants were carried out in UK Apr13-Mar 14 (NHSBT). Values for rates of delayed graft function vary widely: in studies quoted by NICE, they ranged from 24% to 89% depending on donor type and technique used for storage [4].
Renal transplant, prevention of delayed graft function in recipients of a deceased older donor kidney
Intravenous